Stock Movers WH Smith Probe, BBVA Buyback, Ipsen Falls
Dec 19, 2025
Louise Moon, Bloomberg Breaking News editor, dives into major European market movers. She discusses WH Smith's troubling FCA investigation linked to accounting errors and the resulting CEO resignation. The conversation shifts to BBVA's record €4 billion share buyback, a strategic move after a failed takeover bid. Lastly, Louise highlights the disappointing results of Ipsen's drug trial, leading to a significant drop in its shares. Tune in for insights into these market dynamics!
AI Snips
Chapters
Transcript
Episode notes
Regulatory Probe Deepens WH Smith Crisis
- WH Smith faces an FCA probe after an accounting error in its North American business undermined trust in management.
- The CEO resigned, dividends were cut, results were delayed and the stock has plunged about 40% year-to-date.
Buybacks To Close The Sabadell Chapter
- Companies should use share buybacks to signal resolution after failed strategic moves and reassure investors.
- BBVA announced a €4 billion buyback to draw a line under its failed Sabadell bid and stabilize sentiment.
Trial Failure Raises M&A Pressure On Ipsen
- Ipsen's mid-stage oral drug trial for a rare bone disease failed to meet its primary endpoint after five years of study.
- The trial's closure removes a growth lever and increases pressure on Ipsen to pursue M&A to offset competition.